
==== Front
BMC Gastroenterol
BMC Gastroenterol
BMC Gastroenterology
1471-230X
BioMed Central London

39227758
3386
10.1186/s12876-024-03386-6
Research
Causal relationships between neuropsychiatric disorders and nonalcoholic fatty liver disease: A bidirectional Mendelian randomization study
Wang Shisong 12
Gao Hui 2
Lin Pengyao 1
Qian Tianchen 23
Xu Lei xulei22@163.com

2
1 grid.203507.3 0000 0000 8950 5267 Health Science Center, Ningbo University, Ningbo, Zhejiang 315211 China
2 grid.460077.2 0000 0004 1808 3393 Department of Gastroenterology, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang 315010 China
3 https://ror.org/00a2xv884 grid.13402.34 0000 0004 1759 700X Department of Gastroenterology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
4 9 2024
4 9 2024
2024
24 2996 2 2024
26 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Background

Increasing evidences suggest that nonalcoholic fatty liver disease (NAFLD) is associated with neuropsychiatric disorders. Nevertheless, whether there were causal associations between them remained vague. A causal association between neuropsychiatric disorders and NAFLD was investigated in this study.

Methods

We assessed the published genome-wide association study summary statistics for NAFLD, seven mental disorder-related diseases and six central nervous system dysfunction-related diseases. The causal relationships were first assessed using two-sample and multivariable Mendelian randomization (MR). Then, sensitivity analyses were performed, followed by a reverse MR analysis to determine whether reverse causality is possible. Finally, we performed replication analyses and combined the findings from the above studies.

Results

Our meta-analysis results showed NAFLD significantly increased the risk of anxiety disorders (OR = 1.016, 95% CI = 1.010–1.021, P value < 0.0001). In addition, major depressive disorder was the potential risk factor for NAFLD (OR = 1.233, 95% CI = 1.063–1.430, P value = 0.006). Multivariable MR analysis showed that the causal effect of major depressive disorder on NAFLD remained significant after considering body mass index, but the association disappeared after adjusting for the effect of waist circumference. Furthermore, other neuropsychiatric disorders and NAFLD were not found to be causally related.

Conclusions

These results implied causal relationships of NAFLD with anxiety disorders and Major Depressive Disorder. This study highlighted the need to recognize and understand the connection between neuropsychiatric disorders and NAFLD to prevent the development of related diseases.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12876-024-03386-6.

Keywords

Nonalcoholic fatty liver disease
Major depressive disorder; Anxiety disorders
Mendelian randomization
issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

Nonalcoholic fatty liver disease (NAFLD), known as metabolic dysfunction-associated steatotic liver disease (MASLD) [1], affects approximately one in four adults worldwide [2]. And because of its high prevalence, it is currently the liver-related disease with the greatest increase in mortality worldwide [3]. It is related to a higher risk of complications such as end-stage liver disease, hepatocellular carcinoma and cirrhosis in patients with NAFLD [4]. At the same time, mental disorders also carry a high risk of mortality and may worsen over time and are estimated to account for nearly 21.2–32.4% of years lived with disability globally [5]. Related studies have shown that, globally, the greatest risk factor for years lived with disability is neurological and mental health disorders [6]. Therefore, the prevention and treatment of neuropsychiatric disorders and NAFLD are substantial problems warranting attention in clinical work.

Related studies have also suggested that NAFLD can directly affect brain structure through the liver-brain axis [7, 8]. NAFLD has a common pathogenesis with neurological and psychiatric diseases, which are jointly caused by inflammation and oxidative stress pathways [9, 10]. Hence, it is necessary to recognize the interaction between NAFLD and neuropsychiatric disorders. Researchers have discovered a potential connection between them in recent years. In terms of central nervous system disorders, dementia is a neurodegenerative disorder of cognitive dysfunction [11], and Alzheimer's disease is the most common form of dementia [12]. NAFLD contains toxic components that cannot be cleared by the liver, and these may further affect brain function [13]. Several studies have already associated NAFLD with cognitive dysfunction [14, 15]. In terms of mental disorders, a 3-year prospective study hinted that metabolic liver disease including NAFLD is more prevalent in schizophrenia patients [16]; a retrospective cross-sectional study showed that NAFLD patients often have depression and anxiety disorders [17]. However, these associations between NAFLD and neuropsychiatric disorders may in part be affected by confounding or selection bias inherent in conventional observational researches. Furthermore, whether NAFLD is causal or reverse causal in neuropsychiatric disorders remains controversial. Therefore, any potential causal relationship still requires further investigation.

In this context, Mendelian randomization (MR) is a statistical method for assessing exposure factors' causal relationship with disease outcomes [18]. Because genetic variation is completely random during gamete formation and genotypes do not change with disease progression, in MR analysis, the measure of genetic variation, such as a single nucleotide polymorphism (SNP) can be used as an instrument of exposure (IV) or a modifiable risk factor for diseases. Since genetic variation is relatively less susceptible to measurement errors and biases, causal inferences about exposure-outcomes can be strengthened. As a result, causal relationships are explored extensively by MR. Here, we selected seven mental disorder-related diseases and six central nervous system dysfunction-related diseases, performing Two-sample MR to comprehensively assess the association of the risk of NAFLD with those diseases in discovery stage. Multivariate MR was followed immediately to adjust for the potential effects of body mass index (BMI) and waist circumference on the causal relationships. Finally, we performed replication analyses and combined the findings from the above MR studies. In order to examine the inverse effect of NAFLD on neuropsychiatric disorders, we performed a reverse MR analysis (Fig. 1). This study was performed in accordance with the STROBE-MR guidelines (Additional file 1: Table S1).Fig. 1 Design of the bidirectional two-sample Mendelian randomization study. The three core assumptions were as follows: (MRI) relevance assumption; (MRII) independence assumption; and (MRIII) exclusion restriction. PTSD, posttraumatic stress disorder; OCD, obsessive–compulsive disorder; MDD, Major Depressive Disorder; ALS, amyotrophic lateral sclerosis

Methods

Data sources

The data source for our analysis was primarily European populations, which avoided potential bias due to population stratification (Additional file 1: Table S2). Because the data used in the study were published, no ethical approval or informed consent was required. In discovery phase, genetic associations for NAFLD were examined using GWAS, involving 8,434 cases and 770,180 controls [19]. Obtaining a replication phase with data from several leading European tertiary liver centers, which involved 1,483 NAFLD patients and 17,781 control individuals [20]. Schizophrenia is a highly heritable disease with GWAS analysis of 33,640 patients and 43,456 control individuals from the Psychiatric Genomics Consortium (PGC) [21]. Data on bipolar disorder, characterized by severe swings in mood and behavior, were obtained from a meta-analysis of 41,917 patients and 371,549 control individuals [22]. Posttraumatic stress disorder is a common disease in a stressful state after exposure to extreme, life-threatening trauma, and the GWAS data used for its analysis came from the PGC analysis of 23,212 patients and 151,447 control individuals [23]. GWAS data for Major Depressive Disorder (MDD) were also derived from the UK Biobank and PGC (excluding 23andme) analysis of 170,756 patients and 329,443 control individuals [24]. In the International Parkinson's Disease Genomics Consortium, we retrieved a GWAS date included 33,674 patients and 449,056 control individuals [25]. Genetic variants in Alzheimer's disease (AD) were acquired from a large GWAS included 39,106 patients of European ancestry and 46,828 control individuals of European ancestry [26]. Neurodegenerative diseases such as amyotrophic lateral sclerosis can be fatal, and GWAS data were obtained by analyzing 27,205 patients and 110,881 control individuals [27]. The data we selected for epilepsy included 4,382 cases and 453,928 controls [28]. Data on migraine used for analysis included 1,488 cases and 454,860 controls [29]. The study provided us with analytical data on insomnia, encompassing 345,022 cases and 108,357 controls [30]. Mania is clinically manifested by increased speech, disturbed thinking, and elevated mood [31]. Genetic associations for anxiety disorders and mania were obtained by analyzing 29,129 patients and 6,455 control individuals and 7,988 cases and 18,667 controls from UK Biobank (http://www.nealelab.is/uk-biobank), respectively. Obsessive–compulsive disorder is characterized by repetitive behaviors that individuals feel compelled to engage in due to unwanted personal thoughts [32], the GWAS from the FinnGen Biobank were analyzed, including 1,059 patients and 198,110 control individuals (https://r9.finngen.fi/).

Selection of instrumental variables

In order to satisfy the three core MR assumptions, we performed strict filtering steps to control the quality of genetic IVs. 1) We extracted SNPs strongly associated with neuropsychiatric disorders from published GWAS databases and took P < 5 × 10–8 as the initial filter criteria. However, except for AD, schizophrenia, bipolar disorder, MDD, amyotrophic lateral sclerosis, Parkinson's disease and insomnia, SNPs were absent or too few with P values less than 5 × 10–8. Therefore, to select eligible instrumental variables, we expanded the threshold to < 5 × 10–6. SNPs strongly associated with NAFLD for reverse MR analysis are displayed in Additional file 1: Table S3 and S4. 2) SNPs in linkage disequilibrium (LD) were excluded from exposure experiments to ensure the instruments were independent (r2 < 0.001, aggregation window = 10,000 kb). 3) To maintain consistency of the SNPs serving as IVs across the different analyses, we only used variants available for all traits examined and did not replace missing variants with proxies. 4) The F statistic was applied to quantify the intensity of the genetic tool, whose calculation of (beta/se)2 greater than 10 was regarded sufficient [33]. Finally, exposure-associated SNPs were extracted from each result.

MR analysis

In the current study, we applied inverse variance weighting (IVW), the weighted median method and the MR‒Egger method for analysis, and the multiplicative random-effects IVW method was the primary method, followed by sensitivity analysis. In IVW, the Wald estimates associated with the individual SNPs are combined to estimate the causal relationship of exposure on the outcome. It is a weighted regression that transforms the MR estimates into SNP-outcome effects on SNP-exposure effects [34]. MR‒Egger is found on the InSIDE assumption, and the outcome coefficients are linearly weighted regressions on the exposure coefficients, which can also detect small study biases [35]. We can calculate the weighted median estimate of Wald ratio by using the weighted median method that does not require the InSIDE assumption. The analysis of invalid instrumental variables provides 50% of the information, but it can also provide the outcome of causal effect detection [36]. If the results of the IVW method are significant (P < 0.05), even if the results of other methods are not significant, on the basis of no pleiotropic effects and heterogeneity, as long as there are same trends in the beta values of other methods, it is also acceptable and considered a positive result [37]. Multivariable MR (MVMR) can discern the effects of various interrelated factors, suggesting that these factors operate in concert. Consequently, each association identified by MVMR is regarded as a "direct" or "independent" causal link [38]. Thus, we conducted MVMR analysis to adjust for the genetic association of the instruments with BMI and waist circumference.

Sensitivity analysis

MR‒Egger regression was performed to assess whether there was a potential pleiotropic effect, and the intercept item can assess the horizontal pleiotropic effect of its direction; P < 0.05 indicates that there is a potential horizontal pleiotropic effect [39]. The MR pleiotropic residuals and outliers (MR-PRESSO) global test can also be used for horizontal pleiotropic detection. P > 0.05 indicates that there is no level pleiotropy, and pleiotropy refers to genetic variation, which may impact the causal effects [40]. The MR-PRESSO outlier test corrects for pleiotropy by removing outliers, while the outlier test involves at least 50% valid variables, has balanced pleiotropy, and depends on instrument exposure and multiple effects [41]. Heterogeneity was analyzed by applying Rucker's Q test (MR‒Egger regression) and Cochran's Q test (MR-IVW), mainly Cochran's Q test, with P < 0.05. Moreover, I2 was used to quantify heterogeneity (take 0 when I2 is negative). Multiplicity or other causes of heterogeneity were mainly explored with the Q test [42]. Then, the MR-robust adjusted spectral score (MR-RAPS) method was applied to further verify the causality (estimated causal effect) and detect the stability of the analysis, that is, the presence of pleiotropic effects (estimated overdispersion variance trend toward 0 or a P value > 0.05 indicates the absence of horizontal pleiotropic effects) [43]. MR-RAPS can provide unbiased, as well as reliable results, even with weak instrumental variables [44]. What's more, to ensure that the results were robust and consistent, we used leave-one-out analysis [34]. Applying IVW (fixed-effects) to further verify the solidity of the results. In the visual analysis, heterogeneity can be represented by scatter plots, and horizontal pleiotropic effects can be represented by forest plots and funnel plots. Finally, the fixed-effect meta-analysis was performed to assess the integrated causality between NAFLD and neuropsychiatric disorders from MR results of the discovery and replication phases [45, 46]. We chose the results of the meta-analysis as the final causality [47].

Statistical analysis

The association between genetically predicted neuropsychiatric disorders and NAFLD was signaled as the odds ratio (OR) and its 95% confidence interval (95%CI). MR analyses were conducted using R (version 4.3.1) and the "TwoSampleMR", "MR-PRESSO", “MVMR”and "MR. RAPS" software packages. Bonferroni correction was applying to adjust the data because of multiple comparisons. When the observed P < 4.17 × 10–3 (0.05/12), associations were deemed statistically significant evidence of causality. P values between 4.17 × 10–3 and 0.05 were considered suggestive evidence of potential causality.

Result

Instrumental variable selection

In the discovery stage of mental disorders, we extracted 9 SNPs for anxiety disorders, 75 for schizophrenia, 17 for posttraumatic stress disorder, 10 SNPs for obsessive–compulsive disorder, 50 for MDD, 44 SNPs for bipolar disorder, and 13 for mania. For central nervous system disorders, 50 SNPs for AD, 23 SNPs for Parkinson's disease, 11 for epilepsy, 11 SNPs for amyotrophic lateral sclerosis, 14 for migraine and 43 for insomnia were extracted. There was no weak instrumental variable based on the F-statistics, which were all greater than 10. In the replication phase, the same manipulation was performed and sufficiently powerful instrumental variables were extracted. Next, so as to analyze the inverse effect of NAFLD (exposure) on neuropsychiatric disorders (outcome), we included 4 SNPs with a median F value of 59.450 (discovery) and 4 SNPs with a median F value of 49.071 (replication), indicating sufficient heritability. Detailed information on the instrumental variables, such as beta, SE, and P values, can be found in Additional file 1: Tables S3 and S4.

Discovery results

Genetics predict neuropsychiatric disorders on NAFLD

A potential positive causal effect of MDD on NAFLD was demonstrated (OR = 1.210, 95% CI = 1.031–1.420, P value = 0.020) (Table 1). the "leave one out" analysis (Additional file 2: Supplementary Figure S5), the IVW fixed-effects model (OR = 1.210, 95% CI = 1.020–1.436) (Additional file 1: Table S11) and the effect size of MR.RAPS, also suggested the same results. The MR‒Egger regression test (intercept P = 0.214) and the MR-PRESSO global test (P value = 0.696) did not reveal pleiotropy. Meanwhile, no unusual outliers were detected. Cochran's Q test (P value = 0.716) revealed no evidence of heterogeneity (Additional file 1: Table S5). Table 1 The causal effects of NAFLD with the risk of neuropsychiatric disorders in discovery stage

Exposure/
Outcome	Methods	OR	95%CI	Beta	SE	P-value	
Anxiety/NAFLD	IVW	1.124	0.479, 2.639	1.17E-01	0.44	0.789	
	MR Egger	2.160	0.267, 17.441	7.70E-01	1.066	0.493	
	Weighted median	1.124	0.373, 3.386	1.17E-01	0.56	0.835	
Schizophrenia/ NAFLD	IVW	1.013	0.957, 1.072	1.28E-02	0.03	0.658	
	MR Egger	1.271	0.994, 1.625	2.40–01	0.13	0.059	
	Weighted median	0.992	0.918, 1.072	-8.11E-03	0.04	0.838	
PTSD/NAFLD	IVW	0.994	0.899, 1.099	-6.17E-03	0.05	0.906	
	MR Egger	0.989	0.747, 1.308	-1.15E-02	0.14	0.937	
	Weighted median	1.018	0.883, 1.174	1.82E-02	0.07	0.802	
OCD/NAFLD	IVW	0.999	0.967, 1.032	-1.04E-03	0.02	0.950	
	MR Egger	1.036	0.875, 1.227	3.75E-02	0.09	0.689	
	Weighted median	1.020	0.963, 1.080	1.94E-02	0.03	0.506	
MDD/NAFLD	IVW	1.210	1.031, 1.420	1.91E-01	0.08	0.020	
	MR Egger	2.256	0.843, 6.039	8.14E-01	0.50	0.112	
	Weighted median	1.242	0.983, 1.570	2.17E-01	0.12	0.069	
Bipolar disorder/NAFLD	IVW	0.931	0.860, 1.008	-7.16E-02	0.04	0.077	
	MR Egger	0.887	0.591, 1.332	-1.19E-01	0.21	0.567	
	Weighted median	0.919	0.819, 1.031	-8.44E-02	0.06	0.150	
Mania/NAFLD	IVW	1.109	0.747, 1.648	1.04E-01	0.20	0.607	
	MR Egger	2.109	0.663, 6.707	7.46E-01	0.59	0.232	
	Weighted median	1.161	0.617, 2.184	1.49E-01	0.32	0.645	
Alzheimer's disease/NAFLD	IVW	0.964	0.910, 1.021	-3.68E-02	0.03	0.213	
	MR Egger	0.985	0.889, 1.092	-1.51E-02	0.05	0.775	
	Weighted median	0.981	0.899, 1.071	-1.88E-02	0.04	0.674	
Parkinson's disease/NAFLD	IVW	1.027	0.967, 1.090	2.63E-02	0.03	0.390	
	MR Egger	0.964	0.830, 1.120	-3.65E-02	0.08	0.638	
	Weighted median	1.010	0.938, 1.087	9.80E-03	0.04	0.794	
Epilepsy/NAFLD	IVW	1.001	0.924, 1.085	9.49E-04	0.04	0.982	
	MR Egger	0.920	0.803, 1.054	-8.37E-02	0.07	0.259	
	Weighted median	0.947	0.855, 1.049	-5.47E-02	0.05	0.295	
ALS/NAFLD	IVW	1.031	0.895, 1.189	3.09E-02	0.07	0.670	
	MR Egger	1.215	0.833, 1.772	1.95E-01	0.19	0.339	
	Weighted median	1.094	0.928, 1.290	9.02E-02	0.08	0.283	
Migraine/NAFLD	IVW	0.987	0.953, 1.022	-4.77E-02	0.02	0.462	
	MR Egger	1.008	0.905, 1.123	7.71E-03	0.06	0.891	
	Weighted median	0.987	0.942, 1.034	-7.36E-03	0.02	0.585	
Insomnia/NAFLD	IVW	1.865	1.044, 3.333	6.23E-01	0.30	0.035	
	MR Egger	9.869	1.426, 68.288	2.289E-0	0.98	0.025	
	Weighted

median

	1.787	0.798, 4.006	5.81E-01	0.41	0.158	
NAFLD/Anxiety	IVW	1.024	1.001, 1.046	2.35E-02	1.11E-02	0.034	
	MR Egger	1.002	0.942, 1.065	2.97E-03	3.31E-02	0.464	
	Weighted median	1.022	1.002, 1.044	2.25E-02	1.06E-02	0.033	
NAFLD/ Schizophrenia	IVW	0.978	0.880, 1.087	-2.19E-02	0.05	0.684	
	MR Egger	0.857	0.670, 1.097	-1.54E-01	0.12	0.345	
	Weighted median	0.960	0.883, 1.042	-4.12E-02	0.04	0.328	
NAFLD/PTSD	IVW	0.943	0.892, 0.996	-5.88E-02	0.03	0.036	
	MR Egger	0.990	0.790, 1.240	-1.03E-02	0.12	0.937	
	Weighted median	0.957	0.863, 1.060	-4.43E-02	0.05	0.397	
NAFLD/OCD	IVW	0.907	0.666, 1.236	-9.76E-02	0.16	0.536	
	MR Egger	0.719	0.304, 1.701	-3.30E-01	0.44	0.531	
	Weighted median	1.012	0.720, 1.422	1.14E-02	0.17	0.947	
NAFLD/MDD	IVW	0.987	0.956, 1.018	-1.35E-02	0.02	0.405	
	MR Egger	0.956	0.880, 1.038	-4.54E-02	0.04	0.394	
	Weighted median	0.996	0.965, 1.028	-4.38E-03	0.02	0.790	
NAFLD/Bipolar disorder	IVW	0.961	0.917, 1.008	-3.92E-02	0.02	0.103	
	MR Egger	0.989	0.857, 1.141	-1.14E-02	0.07	0.890	
	Weighted median	0.962	0.900, 1.028	-3.90E-02	0.03	0.250	
NAFLD/Mania	IVW	1.001	0.972, 1.031	7.15E-04	1.50E-02	0.962	
	MR Egger	1.024	0.944, 1.111	2.39E-02	4.14E-02	0.622	
	Weighted median	1.001	0.972, 1.030	8.28E-04	1.46E-02	0.954	
NAFLD/ Alzheimer's disease	IVW	0.978	0.881, 1.086	-2.21E-02	5.34E-02	0.679	
	MR Egger	0.976	0.681, 1.398	-2.47E-02	1.84E-01	0.915	
	Weighted median	0.952	0.894, 1.015	-4.85E-02	3.25E-02	0.135	
NAFLD/ Parkinson's disease	IVW	0.957	0.884, 1.037	-4.35E-02	0.04	0.287	
	MR Egger	0.997	0.769, 1.293	-2.80E-03	0.13	0.985	
	Weighted median	0.958	0.850, 1.079	-4.31E-02	0.06	0.478	
NAFLD/Epilepsy	IVW	0.935	0.858, 1.019	-6.72E-02	0.04	0.124	
	MR Egger	1.085	0.828, 1.423	8.19E-02	0.14	0.613	
	Weighted median	0.957	0.847, 1.081	-4.39E-02	0.06	0.480	
NAFLD/ALS	IVW	0.939	0.876, 1.007	-6.27E-02	0.04	0.077	
	MR Egger	0.952	0.877, 1.034	-4.89E-02	0.04	0.246	
	Weighted median	0.981	0.918, 1.049	-1.88E-02	3.38E-02	0.579	
NAFLD/Migraine	IVW	1.140	0.867, 1.497	1.31E-01	0.14	0.349	
	MR Egger	1.411	0.661, 3.011	3.44E-01	0.39	0.467	
	Weighted median	1.164	0.893, 1.518	1.52E-01	0.14	0.261	
NAFLD/Insomnia	IVW	1.002	0.974, 1.032	2.43E-03	0.01	0.869	
	MR Egger	0.974	0.903, 1.052	-2.54E-02	0.04	0.582	
	Weighted

median

	0.995	0.983, 1.008	-4.61E-03	6.50E-03	0.478	
SNP Single nucleotide polymorphism, IVW Inverse-variance weighted, OR Odds ratio, CI Confidence interval, q-value P-value corrected for False Discovery Rate, PTSD Post-traumatic stress disorder, OCD Obsessive–compulsive disorder, MDD Major Depressive Disorder, ALS Amyotrophic lateral sclerosis, NAFLD nonalcoholic fatty liver disease

In addition, we found that insomnia potentially elevated the risk of NAFLD (OR = 1.865, 95% CI = 1.044–3.333, P value = 0.035) (Table 1), the IVW fixed-effects model (OR = 1.865, 95% CI = 1.090–3.192) (Additional file 1: Table S11) also indicated the same trend. Additionally, sensitivity analyses revealed no evidence of pleiotropy (intercepts P = 0.085) or heterogeneity (P value = 0.212).

Genetics predict NAFLD on neuropsychiatric disorders

In reverse MR, the random-effects IVW model showed potential evidence that NAFLD increased the risk of anxiety disorders (OR = 1.024, 95% CI = 1.001–1.046, P value = 0.034) (Table 1). Several other methods, including the "leave one out" analysis (Additional file 2: Supplementary Figure S14), the IVW fixed-effects model (OR = 1.024, 95% CI = 1.006–1.042) (Additional file 1: Table S11) and the effect size of MR.RAPS, also suggested the same causal trend. The MR‒Egger regression test did not indicate horizontal pleiotropic effects (intercept P = 0.857), the MR-PRESSO global test (P value = 0.421) also did not suggest pleiotropic results, and no abnormal outliers were detected. At the same time, MR-RAPS (overdispersion variance P value = 0.704) also indicated that no pleiotropy was present. Cochran's Q test (P value = 0.219) showed no heterogeneity (Additional file 1: Table S6).

Potential negative associations were found between NAFLD and PTSD (OR = 0.943, 95% CI = 0.892–0.996, P value = 0.036) (Table 1). Effect size values for several other methods, including MR.RAPS, also suggested the same causal trend. Sensitivity analyses also failed to observe evidence of any level of pleiotropy (intercepts P = 0.690) or heterogeneity (P value = 0.782).

Some degree of heterogeneity was present (P value = 0.024) in the causal effect of NAFLD on AD. However, there were no pleiotropy and outliers (Additional file 1: Table S6). Therefore, we believed that this result was feasible.

Given the frequent occurrence of obesity in patients with NAFLD, after adjusting for genetically predicted BMI and waist circumference, we performed MVMR for anxiety disorders, schizophrenia, MDD, bipolar disorder, AD and insomnia. Our results showed that MMD remained a potential risk factor for NAFLD after adjusting for genetically predicted BMI (OR = 1.334, 95% CI = 1.054–1.687, P value = 0.016), which confirmed the robustness of the results. However, once we accounted for waist circumference, the causal connection between MDD and NAFLD disappeared, indicating that this relationship might be influenced by waist circumference. Additionally, there was no significant link between insomnia and NAFLD, suggesting that BMI and waist circumference might influence this association. For the other diseases, no connections were observed either. (Additional file 1: Table S7).

Replication results

In reverse MR, the random-effects IVW model showed significant evidence that NAFLD increased the risk of anxiety disorders (OR = 1.015, 95% CI = 1.010–1.021, P value = 9.24 × 10–9) (Table 2). The "leave one out" analysis (Additional file 2: Supplementary Figure S40) and fixed-effects model (Additional file 1: Table S11) demonstrated the robustness of the results (OR = 1.015, 95% CI = 1.007–1.024). Furthermore, sensitivity analyses also didn’t observe evidence of any level of pleiotropy (intercepts P = 0.415) or heterogeneity (P value = 0.763). Table 2 The causal effects of NAFLD with the risk of neuropsychiatric disorders in replication stage

Exposure/
Outcome	Methods	OR	95%CI	Beta	SE	P-value	
Anxiety/NAFLD	IVW	0.980	0.074, 12.891	-2.05E-02	1.31	0.988	
	MR Egger	62.883	0.140, 28,329.898	4.141E-00	3.12	0.226	
	Weighted median	1.748	0.076, 40.042	5.58E-01	1.60	0.727	
Schizophrenia/ NAFLD	IVW	1.032	0.935, 1.137	3.10E-02	0.05	0.534	
	MR Egger	1.072	0.614, 1.871	6.92E-02	0.28	0.808	
	Weighted median	1.017	0.892, 1.159	1.67E-02	0.07	0.802	
PTSD/NAFLD	IVW	0.978	0.914, 1.047	-2.20E-02	0.03	0.526	
	MR Egger	0.880	0.474, 1.634	-1.28E-01	0.32	0.690	
	Weighted median	0.987	0.917, 1.062	-1.32E-02	0.04	0.724	
OCD/NAFLD	IVW	1.034	0.893, 1.196	3.33E-02	0.07	0.656	
	MR Egger	1.057	0.657, 1.700	5.55E-02	0.24	0.825	
	Weighted median	1.101	0.913, 1.328	9.62E-02	0.10	0.314	
MDD/NAFLD	IVW	1.380	0.931, 2.045	3.22E-01	0.20	0.108	
	MR Egger	1.731	0.313, 9.569	5.49E-01	0.87	0.532	
	Weighted median	1.643	0.965, 2.795	4.96E-01	0.27	0.067	
Bipolar disorder/NAFLD	IVW	1.019	0.966, 1.076	1.93E-02	0.03	0.485	
	MR Egger	1.273	0.789, 2.054	2.42E-01	0.24	0.327	
	Weighted median	1.018	0.946, 1.096	1.81E-02	0.04	0.630	
Mania/NAFLD	IVW	0.523	0.238, 1.152	-6.47E-01	0.40	0.108	
	MR Egger	1.458	0.098, 21.786	3.77E-01	1.38	0.791	
	Weighted median	0.785	0.235, 2.617	-2.42E-01	0.61	0.694	
Alzheimer's disease/NAFLD	IVW	0.990	0.934, 1.050	-9.93E-03	0.03	0.739	
	MR Egger	1.085	0.863, 1.364	8.15E-02	0.12	0.489	
	Weighted median	0.990	0.929, 1.054	-1.04E-02	0.03	0.745	
Parkinson's disease/NAFLD	IVW	0.989	0.924, 1.059	-1.06E-02	0.03	0.761	
	MR Egger	1.002	0.906, 1.108	1.62E-03	0.05	0.975	
	Weighted median	0.984	0.910, 1.064	-1.61E-02	0.04	0.685	
Epilepsy/NAFLD	IVW	0.897	0.773, 1.042	-1.08E-01	0.08	0.156	
	MR Egger	0.881	0.687, 1.129	-1.27E-01	0.13	0.340	
	Weighted median	0.955	0.794, 1.148	-4.64E-02	0.09	0.623	
ALS/NAFLD	IVW	1.073	0.856, 1.345	7.07E-02	0.12	0.539	
	MR Egger	0.783	0.444, 1.378	-2.45E-01	0.29	0.416	
	Weighted median	1.089	0.788, 1.505	8.54E-02	0.16	0.605	
Migraine/NAFLD	IVW	0.931	0.824, 1.051	-7.16E-02	0.06	0.248	
	MR Egger	0.881	0.638, 1.218	1.26E-01	0.17	0.458	
	Weighted median	0.920	0.780, 1.085	-8.38E-02	0.08	0.320	
Insomnia/NAFLD	IVW	0.947	0.598, 1.497	-5.49E-02	0.23	0.814	
	MR Egger	1.888	0.019, 189.369	6.36E-01	2.35	0.788	
	Weighted median	0.918	0.568, 1.483	-8.61E-02	0.24	0.725	
NAFLD/Anxiety	IVW	1.015	1.010, 1.021	1.54E-02	2.68E-03	9.24E-09	
	MR Egger	1.003	0.979, 1.028	3.27E-03	1.26E-02	0.819	
	Weighted median	1.014	1.004, 1.024	1.39E-02	5.08E-03	6.20E-03	
NAFLD/ Schizophrenia	IVW	0.998	0.949, 1.049	-2.08E-03	0.03	0.935	
	MR Egger	0.916	0.807, 1.039	-8.78E-02	0.06	0.305	
	Weighted median	0.995	0.956, 1.037	-4.63E-03	0.02	0.824	
NAFLD/PTSD	IVW	0.992	0.942, 1.043	-8.49E-03	0.03	0.744	
	MR Egger	0.944	0.799, 1.115	-5.75E-02	0.09	0.569	
	Weighted median	0.989	0.941, 1.040	-1.08E-02	0.03	0.672	
NAFLD/OCD	IVW	0.919	0.788, 1.071	-8.48E-02	0.08	0.277	
	MR Egger	1.041	0.628, 1.725	4.05E-02	0.26	0.890	
	Weighted median	0.972	0.838, 1.127	-2.88E-02	0.08	0.703	
NAFLD/MDD	IVW	1.001	0.977, 1.025	7.88E-04	0.01	0.949	
	MR Egger	0.963	0.903, 1.026	-3.79E-02	0.03	0.364	
	Weighted median	1.002	0.987, 1.017	2.19E-03	0.01	0.773	
NAFLD/Bipolar disorder	IVW	0.995	0.946, 1.046	-5.36E-03	0.03	0.835	
	MR Egger	0.937	0.800, 1.097	-6.53E-02	0.08	0.502	
	Weighted median	0.990	0.959, 1.023	-9.63E-03	0.02	0.557	
NAFLD/Mania	IVW	1.006	0.997, 1.016	6.50E-03	4.77E-03	0.173	
	MR Egger	1.001	0.9671.036	9.45E-04	1.75E-02	0.962	
	Weighted median	1.002	0.989, 1.016	2.05E-03	6.85E-03	0.764	
NAFLD/ Alzheimer's disease	IVW	0.993	0.956, 1.031	-7.28E-03	0.02	0.704	
	MR Egger	0.946	0.846, 1.059	-5.52E-02	0.06	0.437	
	Weighted median	0.993	0.965, 1.022	-7.26E-03	0.01	0.622	
NAFLD/ Parkinson's disease	IVW	0.961	0.908, 1.017	-3.94E-02	0.03	0.172	
	MR Egger	1.058	0.915, 1.223	5.63E-02	0.07	0.526	
	Weighted median	0.978	0.922, 1.037	-2.25E-02	0.03	0.451	
NAFLD/Epilepsy	IVW	1.003	0.969, 1.039	3.46E-03	0.02	0.847	
	MR Egger	0.958	0.833, 1.103	-4.27E-02	0.07	0.612	
	Weighted median	0.990	0.938, 1.044	-1.05E-02	0.03	0.701	
NAFLD/ALS	IVW	0.984	0.948, 1.021	-1.59E-02	0.02	0.399	
	MR Egger	0.946	0.841, 1.064	-5.60E-02	0.06	0.450	
	Weighted median	0.986	0.948, 1.026	-1.38E-02	0.02	0.492	
NAFLD/Migraine	IVW	1.101	0.966, 1.254	9.60E-02	0.07	0.149	
	MR Egger	0.866	0.630, 1.190	-1.44E-01	0.16	0.469	
	Weighted median	1.053	0.929, 1.193	5.15E-02	0.06	0.420	
NAFLD/Insomnia	IVW	0.998	0.989, 1.007	-2.10E-03	4.61E-03	0.650	
	MR Egger	0.990	0.961, 1.021	-9.86E-03	0.02	0.588	
	Weighted median	0.995	0.990, 1.000	-5.00E-03	2.71E-03	0.065	
SNP Single nucleotide polymorphism, IVW Inverse-variance weighted, OR Odds ratio, CI Confidence interval, q-value P-value corrected for False Discovery Rate, PTSD Post-traumatic stress disorder, OCD Obsessive–compulsive disorder, MDD Major Depressive Disorder, ALS Amyotrophic lateral sclerosis, NAFLD nonalcoholic fatty liver disease

Some degree of heterogeneity was present (P value = 0.013) in the causal effect of NAFLD on MDD. There was also some degree of heterogeneity in the causal effect of NAFLD on Bipolar Disorder and insomnia, as indicated by a P-values of 0.017 and 0.002. However, there were no pleiotropy and outliers (Additional file 1: Table S9). Hence, we considered this outcome to be achievable.

Combined results from the meta-analysis

Pooled analysis suggested that MDD was the potential risk factor for NAFLD (OR = 1.233, 95% CI = 1.063–1.430, P value = 0.006) (Fig. 2 and Additional file 1: Table S10). The fixed-effect model of MDD suggested the same results (OR = 1.241, 95% CI = 1.064–1.447, P value = 0.006). Meta-analysis also showed significant evidence that NAFLD increased the risk of anxiety disorders (OR = 1.016, 95% CI = 1.010–1.021, P value < 0.0001) (Fig. 3), and fixed-effects model (Additional file 1: Table S11) demonstrated the robustness of the results (OR = 1.017, 95% CI = 1.009–1.024, P value < 0.0001).Fig. 2 The effects of neuropsychiatric disorders on NAFLD were estimated by Meta-analysis using IVW. OR, odds ratio; CI, confidence interval; IVW, inverse-variance weighted method; PTSD, posttraumatic stress disorder; OCD, obsessive–compulsive disorder; MDD, Major Depressive Disorder; ALS, amyotrophic lateral sclerosis

Fig. 3 The effects of NAFLD on neuropsychiatric disorders were estimated by Meta-analysis using IVW. OR, odds ratio; CI, confidence interval; IVW, inverse-variance weighted method; PTSD, posttraumatic stress disorder; OCD, obsessive–compulsive disorder; MDD, Major Depressive Disorder; ALS, amyotrophic lateral sclerosis

In addition, there was no causal connection between NAFLD and other neuropsychiatric disorders (all P values > 0.05), nor was any level of pleiotropy or heterogeneity observed (Additional file 1: Tables S5, S6, S8, S9). The visual analyses of the discovery (Additional file 2: Supplementary Figures S1-S26) and replication (Additional file 2: Supplementary Figures S27-S52) stages can be found in Supplementary materials.

Discussion

This bidirectional Mendelian randomization study leveraged genetic data from a large number of published GWASs to explore a bidirectional hypothetical causal association between NAFLD and neuropsychiatric disorders. From a genetic perspective, our results revealed that MDD was the potential risk factor for NAFLD, and NAFLD also increased significantly the risk of anxiety disorders.

Anxiety disorders are common in Western populations [48]. A study comparing 19,871 NAFLD patients with 19,871 matched control individuals found that new-onset anxiety disorders was linked to NAFLD even after multiple complications were controlled [48]. In a cross-sectional study conducted in the United States, depression and anxiety symptoms were evaluated using scale scores in 567 patients diagnosed with NAFLD through biopsy [49], 45% and 25% of the patients had subclinical and clinical anxiety symptoms, respectively, indicating that anxiety disorders is one of the common symptoms of NAFLD and that it is related to advanced NAFLD. On the other hand, to some extent, NAFLD may progress to nonalcoholic steatohepatitis (NASH) [50]. A smaller study involving 36 NASH patients and 36 control individuals without liver disease after cholecystectomy revealed that NASH increased the risk of anxiety disorders than the control group. It was also found that anxiety disorders was related to more serious changes in liver histological characteristics [51]. This is consistent with the evidence that NAFLD increased significantly the risk of anxiety disorders observed in our MR study.

MDD is a common recurrent mental illness that leads to decreased quality of life and increased mortality in the relevant population [52]. After adjusting for genetically predicted BMI, our findings indicated that MDD continued to be a potential risk factor for NAFLD. However, after adjusting for waist circumference, the association disappeared. This suggested that multiple factors impact the relationship between them, and future research should further explore the offset effects of these factors. In patients with depression, biological disturbances related to obesity are linked to a prolonged course of the disease and negative reactions to conventional antidepressant therapies [53]. Meantime, many studies have found a high prevalence of MDD in patients with NAFLD [54, 55]. A study found that NAFLD patients with MDD had more severe histological liver steatosis and higher NAFLD activity scores compared with NAFLD patients without MDD [56]. Pathologically, MDD is associated with a severe hepatocellular balloon [49], which is one of the characteristics of NAFLD [57]. In another aspect, the rising levels of inflammatory markers in depressed patients, such as intercytotin-6, C-reactive protein and tumor necrosis factor α [58], provide another reasonable explanation for the association with NAFLD. Meta-analyzing the results of nine longitudinal studies showed that depression was an independent risk factor for diabetes [59]. Moreover, depression triggers activity in the HPA axis and the sympathetic nervous system, which leads to the secretion of the stress hormone cortisol. Elevated cortisol levels promote the breakdown of fats and the release of free fatty acids into the bloodstream. Concurrently, cortisol suppresses insulin production and reduces the body's sensitivity to insulin [60]. Meantime, insulin resistance is tightly related to NAFLD. Insulin resistance may also lead to damage to the mitochondrial fatty acid β-oxidation pathway, increasing free fatty acids and other lipids in the body. This may lead to endothelial dysfunction, resulting in a proinflammatory state in the body [61], and increasing the incidence of NAFLD.

Our MR results found no causal relationship between NAFLD and AD, which goes against the previous studies. However, these studies were basically cross-sectional studies, and the longitudinal associations between them should still be supported by further research data. At the same time, there are also many studies showing that there is no significant direct correlation between NAFLD and AD [62, 63]. As mentioned above, differences in the mean ages of the study population and the cognitive level tests used are also responsible. And the severity of liver fibrosis with disease progression (rather than NAFLD itself) may be associated with cognitive dysfunction [64, 65]. Numerous studies also emphasize the influence of fibrosis severity on the development of diseases such as cardiovascular dysfunction [66] and stroke [67]).

The results of this study contradict previous observational studies that reported a link between schizophrenia and NAFLD. Similarly, it has been reported that there may be a causal link between bipolar disorder and NAFLD [68], but this is not consistent with our results. The results may be affected by the confusion or selection bias inherent in traditional observational studies, such as differences in diet structure, lifestyle and genetic susceptibility of different populations. The connection between NAFLD and these factors may be caused by lots of factors rather than simply the disease itself. For example, a research explained that the use of atypical antipsychotic drugs for the treatment of schizophrenia and other diseases will produce many metabolic and endocrine-related side effects, like insulin resistance, dyslipidemia and systemic inflammation, which will increased the risk of NAFLD [69]. And antidepressants have been shown to be associated with hyperglycemia [70]. As a study showed that MDD was not associated with an increased risk of any cardiovascular disease, and the use of antidepressants increased the risk of multiple cardiovascular diseases [71]. In young male patients, different drug doses and combinations are also risk factors for NAFLD [72]. Although glucose homeostasis is altered before the onset of schizophrenia [73], these only suggest that both have a similar pathogenesis. The possible potential causal relationships between them still need to be further explored.

Schizophrenia and AD, similar in many clinical and pathophysiological features, may accelerate brain aging by promoting neuroinflammation [74] and show similarities in white matter damage patterns [75]. Therefore, the causal link between them and NAFLD may also share similarities, which is consistent with our findings.

In discovery stage, we found that insomnia was a risk factor for NAFLD, while the results of the meta-analysis indicated no causal relationship between them. In the MVMR analysis, there was still no significant association between them. Therefore, the connection between them should still be further evaluated. Insomnia is usually defined by asking "Do you have trouble falling asleep or staying asleep?" [76] Multiple studies indicated that short sleep duration may cause an increase in insulin resistance [77], a significant decrease in antioxidant activity and significantly higher levels of lipid peroxidation [78]. Furthermore, the concentrations of gamma glutamyl transpeptidase and 8-hydroxydeoxyguanosine are often elevated in the serum of NAFLD patients, suggesting that oxidative stress may have occurred [79]. However, a study found that the incidence of insomnia did not seem to be significantly different in NAFLD patients compared to the general population, and the severity of inflammation-related histology may not play a critical role in the pathogenesis of insomnia in NAFLD patients [80]. In conclusion, there may be no direct causal relationship between insomnia and NAFLD, and the association between them may result from a combination of multiple factors.

A cross-sectional study suggested that there was no significant relationship between NAFLD and migraine [81], which is consistent with our results. Although a study has found that there may be a causal relationship [82], we believe that the sample size used is too small and the appropriate control cases are not used, so the causal relationship between them still needs further studies to verify.

Alternatively, socioeconomic status consists mainly of income and education level, the genetic liability of which may play a role in the outcome of mental and physical health. Intelligence can be seen as an individual's innate mental capacity, whereas education reflects the process of socialization from birth through adulthood, with income being an outcome of this process [83]. A study showed that higher income levels are effective in reducing the incidence of psychiatric disorders, and that a higher genetic liability for education may increase the occurrence of mental health problems independently of salary change [84]. On the other hand, higher education can reduce the occurrence of NAFLD, and the income level is independent of it [85]. Hence, the link between NAFLD and neuropsychiatric disorders within socioeconomic contexts requires deeper investigation, and upcoming public health initiatives could gain from the careful utilization of research on social environments and genetics.

The main strength of our study was that the MR design avoids the confusion or selection bias common in traditional observational studies and supports a robust causal relationships between exposure and results. Besides, our study used aggregate data from large genetic databases, which made our research assumptions more accurate. The use of multiple sensitivity analyses combined with "leave one out" analysis enabled the testing of the stability of key results and provided additional reliable evidence. In addition, this was a MVMR and bidirectional causal-association study that expands the evidence on the relationships between neuropsychiatric disorders and NAFLD. Finally, this analysis had guiding recommendations for future studies on MASLD.

However, our research also had some limitations. First, the population studied was exclusively of European descent; therefore, further studies should be encouraged to verify these results in other populations. Second, although the sensitivity analysis did not reveal any evidence of multiple effects that may affect the results, the potential for horizontal pleiotropic effects couldn’t be completely excluded. Third, we chose some disease-related instruments with a relatively loose threshold of 5 × 10–6, which was considered to be a reasonable threshold [86, 87], but it will affect the statistical efficacy of causal estimation to some extent. Furthermore, since some databases are not publicly available, databases such as MMD and insomnia were not the largest used in our study. Moreover, given that the data analysis should be all European populations, our database for schizophrenia analysis was not the largest. Finally, in studies, exposure and outcome were not only likely to have potentially duplicate participants, but it was also difficult to predict the extent to which the sample overlap. However, in this study, the use of sufficiently powerful tool variables (F statistics > 10) could minimize the potential deviation caused by sample overlap [33].

In summary, our study implied causal relationships of NAFLD with MDD and anxiety disorders. For other related diseases, more genetic instruments and larger GWAS data are needed to verify the results. On the other hand, our study further verified the bidirectional causality between NAFLD and neuropsychiatric disorders.

Supplementary Information

Additional file 1: Table S10. Meta-analysis in the multiplicative random-effects IVW method.

Additional file 2: Supplementary Figure S1. Forest plot (A), Leave-one-out plot (B), scatter plot (C) and funnel plot (D) of the causal effect of anxiety on NAFLD.

Abbreviations

NAFLD Nonalcoholic fatty liver disease

OR Odds ratio

CI Confidence interval

MR Mendelian randomization;

MVMR Multivariable Mendelian randomization

SNP Single nucleotide polymorphism

IV Instrumental variable

GWAS Genome-wide association study

IVW Inverse-variance weighted

PGC Psychiatric Genomics Consortium

AD Alzheimer's disease

PTSD Post-traumatic stress disorder

MDD Major Depressive Disorder

OCD Obsessive-compulsive disorder

ALS Amyotrophic lateral sclerosis

BMI Body mass index

Acknowledgements

We would like to thank the UK Biobank consortia, FinnGen consortia, IPDGC consortia, PGC consortia and European tertiary liver centers for contributing data.

Author contributions

L. Xu conceived the study design. S. Wang and H. Gao performed the statistical analysis. S. Wang and H. Gao wrote the manuscript. T. Qian and P. Lin reviewed the manuscript. S. Wang and H. Gao contributed equally to this work. All authors approved the submitted draft.

Funding

This work was supported by the Ningbo Top Medical and Health Research Program (No. 2023020612), the Ningbo Leading Medical & Healthy Discipline Project (2022-S04), and the Medical Health Science and Technology Project of Zhejiang Provincial Health Commission (No. 2022KY315). Ningbo Science and Technology Public Welfare project (No. 2023S133). The Ningbo City Medical Science and Technology project (No. 2019Y71).

Availability of data and materials

All data generated or analysed during this study are included in this published article (and its supplementary information files).

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Shisong Wang and Hui Gao contributed equally to this work.
==== Refs
References

1. Song SJ, Lai JC, Wong GL, Wong VW, Yip TC. Can we use old NAFLD data under the new MASLD definition? J Hepatol. 2024;80(2):e54–e56.
2. Powell EE Wong VW Rinella M Non-alcoholic fatty liver disease Lancet 2021 397 10290 2212 2224 10.1016/S0140-6736(20)32511-3 33894145
Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397(10290):2212–24.33894145 10.1016/S0140-6736(20)32511-3
3. Paik JM Golabi P Younossi Y Mishra A Younossi ZM Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD Hepatology (Baltimore, MD) 2020 72 5 1605 1616 10.1002/hep.31173 32043613
Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM. Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD. Hepatology (Baltimore, MD). 2020;72(5):1605–16.32043613 10.1002/hep.31173
4. W M. The Diagnostic Evaluation of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH). Gastroenterology & Hepatology International Journal. 2019;4(2):1–14.
5. Gurillo P Jauhar S Murray RM MacCabe JH Does tobacco use cause psychosis? Systematic review and meta-analysis Lancet Psychiatry 2015 2 8 718 725 10.1016/S2215-0366(15)00152-2 26249303
Gurillo P, Jauhar S, Murray RM, MacCabe JH. Does tobacco use cause psychosis? Systematic review and meta-analysis Lancet Psychiatry. 2015;2(8):718–25.26249303 10.1016/S2215-0366(15)00152-2
6. Whiteford HA Ferrari AJ Degenhardt L Feigin V Vos T The global burden of mental, neurological and substance use disorders: an analysis from the Global Burden of Disease Study 2010 PLoS ONE 2015 10 2 e0116820 10.1371/journal.pone.0116820 25658103
Whiteford HA, Ferrari AJ, Degenhardt L, Feigin V, Vos T. The global burden of mental, neurological and substance use disorders: an analysis from the Global Burden of Disease Study 2010. PLoS ONE. 2015;10(2).25658103 10.1371/journal.pone.0116820
7. Jakhmola-Mani R Islam A Katare DP Liver-Brain Axis in Sporadic Alzheimer's Disease: Role of Ten Signature Genes in a Mouse Model CNS Neurol Disord: Drug Targets 2021 20 9 871 885 10.2174/1871527319666201209111006 33297922
Jakhmola-Mani R, Islam A, Katare DP. Liver-Brain Axis in Sporadic Alzheimer’s Disease: Role of Ten Signature Genes in a Mouse Model. CNS Neurol Disord: Drug Targets. 2021;20(9):871–85.33297922 10.2174/1871527319666201209111006
8. Hadjihambi A Konstantinou C Klohs J Monsorno K Le Guennec A Donnelly C Partial MCT1 invalidation protects against diet-induced non-alcoholic fatty liver disease and the associated brain dysfunction J Hepatol 2023 78 1 180 190 10.1016/j.jhep.2022.08.008 35995127
Hadjihambi A, Konstantinou C, Klohs J, Monsorno K, Le Guennec A, Donnelly C, et al. Partial MCT1 invalidation protects against diet-induced non-alcoholic fatty liver disease and the associated brain dysfunction. J Hepatol. 2023;78(1):180–90.35995127 10.1016/j.jhep.2022.08.008
9. Caldwell SH Swerdlow RH Khan EM Iezzoni JC Hespenheide EE Parks JK Mitochondrial abnormalities in non-alcoholic steatohepatitis J Hepatol 1999 31 3 430 434 10.1016/S0168-8278(99)80033-6 10488700
Caldwell SH, Swerdlow RH, Khan EM, Iezzoni JC, Hespenheide EE, Parks JK, et al. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol. 1999;31(3):430–4.10488700 10.1016/S0168-8278(99)80033-6
10. Milaneschi Y Lamers F Berk M Penninx B Depression Heterogeneity and Its Biological Underpinnings: Toward Immunometabolic Depression Biol Psychiat 2020 88 5 369 380 10.1016/j.biopsych.2020.01.014 32247527
Milaneschi Y, Lamers F, Berk M, Penninx B. Depression Heterogeneity and Its Biological Underpinnings: Toward Immunometabolic Depression. Biol Psychiat. 2020;88(5):369–80.32247527 10.1016/j.biopsych.2020.01.014
11. McKhann GM Knopman DS Chertkow H Hyman BT Jack CR Jr Kawas CH The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimer's Dementia 2011 7 3 263 269 10.1016/j.jalz.2011.03.005 21514250
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dementia. 2011;7(3):263–9.21514250 10.1016/j.jalz.2011.03.005
12. Alzheimer's disease facts and figures Alzheimer's Dementia 2021 17 3 327 406 10.1002/alz.12328
Alzheimer’s disease facts and figures. Alzheimer’s Dementia. 2021;17(3):327–406.10.1002/alz.12328
13. Kabir MT Uddin MS Zaman S Begum Y Ashraf GM Bin-Jumah MN Molecular Mechanisms of Metal Toxicity in the Pathogenesis of Alzheimer's Disease Mol Neurobiol 2021 58 1 1 20 10.1007/s12035-020-02096-w 32889653
Kabir MT, Uddin MS, Zaman S, Begum Y, Ashraf GM, Bin-Jumah MN, et al. Molecular Mechanisms of Metal Toxicity in the Pathogenesis of Alzheimer’s Disease. Mol Neurobiol. 2021;58(1):1–20.32889653 10.1007/s12035-020-02096-w
14. Seo SW Gottesman RF Clark JM Hernaez R Chang Y Kim C Nonalcoholic fatty liver disease is associated with cognitive function in adults Neurology 2016 86 12 1136 1142 10.1212/WNL.0000000000002498 26911638
Seo SW, Gottesman RF, Clark JM, Hernaez R, Chang Y, Kim C, et al. Nonalcoholic fatty liver disease is associated with cognitive function in adults. Neurology. 2016;86(12):1136–42.26911638 10.1212/WNL.0000000000002498
15. Elliott C Frith J Day CP Jones DE Newton JL Functional impairment in alcoholic liver disease and non-alcoholic fatty liver disease is significant and persists over 3 years of follow-up Dig Dis Sci 2013 58 8 2383 2391 10.1007/s10620-013-2657-2 23609794
Elliott C, Frith J, Day CP, Jones DE, Newton JL. Functional impairment in alcoholic liver disease and non-alcoholic fatty liver disease is significant and persists over 3 years of follow-up. Dig Dis Sci. 2013;58(8):2383–91.23609794 10.1007/s10620-013-2657-2
16. Galiano Rus S, Ortiz García de la Foz V, Arias-Loste MT, Iruzubieta P, Gómez-Revuelta M, Juncal-Ruiz M, et al. Elevated risk of liver steatosis in first-episode psychosis patients: Results from a 3-year prospective study. Schizophrenia research. 2022;246:30–8.
17. Choi JM Chung GE Kang SJ Kwak MS Yang JI Park B Association Between Anxiety and Depression and Nonalcoholic Fatty Liver Disease Front Med (Lausanne) 2020 7 585618 10.3389/fmed.2020.585618 33537324
Choi JM, Chung GE, Kang SJ, Kwak MS, Yang JI, Park B, et al. Association Between Anxiety and Depression and Nonalcoholic Fatty Liver Disease. Front Med (Lausanne). 2020;7.33537324 10.3389/fmed.2020.585618
18. Sekula P Del Greco MF Pattaro C Kottgen A Mendelian Randomization as an Approach to Assess Causality Using Observational Data J Am Soc Nephrol 2016 27 11 3253 3265 10.1681/ASN.2016010098 27486138
Sekula P, Del Greco MF, Pattaro C, Kottgen A. Mendelian Randomization as an Approach to Assess Causality Using Observational Data. J Am Soc Nephrol. 2016;27(11):3253–65.27486138 10.1681/ASN.2016010098
19. Anstee QM Darlay R Cockell S Meroni M Govaere O Tiniakos D Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆ J Hepatol 2020 73 3 505 515 10.1016/j.jhep.2020.04.003 32298765
Anstee QM, Darlay R, Cockell S, Meroni M, Govaere O, Tiniakos D, et al. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆. J Hepatol. 2020;73(3):505–15.32298765 10.1016/j.jhep.2020.04.003
20. Namjou B Lingren T Huang Y Parameswaran S Cobb BL Stanaway IB GWAS and enrichment analyses of non-alcoholic fatty liver disease identify new trait-associated genes and pathways across eMERGE Network BMC Med 2019 17 1 135 10.1186/s12916-019-1364-z 31311600
Namjou B, Lingren T, Huang Y, Parameswaran S, Cobb BL, Stanaway IB, et al. GWAS and enrichment analyses of non-alcoholic fatty liver disease identify new trait-associated genes and pathways across eMERGE Network. BMC Med. 2019;17(1):135.31311600 10.1186/s12916-019-1364-z
21. Consortium SWGotPG. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511(7510):421–7.
22. Mullins N Forstner AJ O'Connell KS Coombes B Coleman JRI Qiao Z Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology Nat Genet 2021 53 6 817 829 10.1038/s41588-021-00857-4 34002096
Mullins N, Forstner AJ, O’Connell KS, Coombes B, Coleman JRI, Qiao Z, et al. Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. Nat Genet. 2021;53(6):817–29.34002096 10.1038/s41588-021-00857-4
23. Nievergelt CM, Maihofer AX, Klengel T, Atkinson EG, Chen C-Y, Choi KW, et al. International meta-analysis of PTSD genome-wide association studies identifies sex- and ancestry-specific genetic risk loci. Nat Commun. 2019;10(1):4558.
24. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. The Lancet. 2013;381(9875):1371–9.
25. Nalls MA Blauwendraat C Vallerga CL Heilbron K Bandres-Ciga S Chang D Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies The Lancet Neurology 2019 18 12 1091 1102 10.1016/S1474-4422(19)30320-5 31701892
Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: a meta-analysis of genome-wide association studies. The Lancet Neurology. 2019;18(12):1091–102.31701892 10.1016/S1474-4422(19)30320-5
26. Kunkle BW Grenier-Boley B Sims R Bis JC Damotte V Naj AC Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing Nat Genet 2019 51 3 414 430 10.1038/s41588-019-0358-2 30820047
Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, et al. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat Genet. 2019;51(3):414–30.30820047 10.1038/s41588-019-0358-2
27. van Rheenen W van der Spek RAA Bakker MK van Vugt J Hop PJ Zwamborn RAJ Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology Nat Genet 2021 53 12 1636 1648 10.1038/s41588-021-00973-1 34873335
van Rheenen W, van der Spek RAA, Bakker MK, van Vugt J, Hop PJ, Zwamborn RAJ, et al. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nat Genet. 2021;53(12):1636–48.34873335 10.1038/s41588-021-00973-1
28. Sakaue S Kanai M Tanigawa Y Karjalainen J Kurki M Koshiba S A cross-population atlas of genetic associations for 220 human phenotypes Nat Genet 2021 53 10 1415 1424 10.1038/s41588-021-00931-x 34594039
Sakaue S, Kanai M, Tanigawa Y, Karjalainen J, Kurki M, Koshiba S, et al. A cross-population atlas of genetic associations for 220 human phenotypes. Nat Genet. 2021;53(10):1415–24.34594039 10.1038/s41588-021-00931-x
29. Jiang L Zheng Z Fang H Yang J A generalized linear mixed model association tool for biobank-scale data Nat Genet 2021 53 11 1616 1621 10.1038/s41588-021-00954-4 34737426
Jiang L, Zheng Z, Fang H, Yang J. A generalized linear mixed model association tool for biobank-scale data. Nat Genet. 2021;53(11):1616–21.34737426 10.1038/s41588-021-00954-4
30. Lane JM Jones SE Dashti HS Wood AR Aragam KG van Hees VT Biological and clinical insights from genetics of insomnia symptoms Nat Genet 2019 51 3 387 393 10.1038/s41588-019-0361-7 30804566
Lane JM, Jones SE, Dashti HS, Wood AR, Aragam KG, van Hees VT, et al. Biological and clinical insights from genetics of insomnia symptoms. Nat Genet. 2019;51(3):387–93.30804566 10.1038/s41588-019-0361-7
31. Martino DJ, Valerio MP, Parker G. The structure of mania: An overview of factorial analysis studies. Eur Psychiatry. 2020;63(1):e10.
32. Goodman WK Storch EA Sheth SA Harmonizing the Neurobiology and Treatment of Obsessive-Compulsive Disorder Am J Psychiatry 2021 178 1 17 29 10.1176/appi.ajp.2020.20111601 33384007
Goodman WK, Storch EA, Sheth SA. Harmonizing the Neurobiology and Treatment of Obsessive-Compulsive Disorder. Am J Psychiatry. 2021;178(1):17–29.33384007 10.1176/appi.ajp.2020.20111601
33. Pierce BL Ahsan H Vanderweele TJ Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants Int J Epidemiol 2011 40 3 740 752 10.1093/ije/dyq151 20813862
Pierce BL, Ahsan H, Vanderweele TJ. Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants. Int J Epidemiol. 2011;40(3):740–52.20813862 10.1093/ije/dyq151
34. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base platform supports systematic causal inference across the human phenome. eLife. 2018;7:e34408.
35. Bowden J Davey Smith G Burgess S Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression Int J Epidemiol 2015 44 2 512 525 10.1093/ije/dyv080 26050253
Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512–25.26050253 10.1093/ije/dyv080
36. Bowden J Davey Smith G Haycock PC Burgess S Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator Genet Epidemiol 2016 40 4 304 314 10.1002/gepi.21965 27061298
Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet Epidemiol. 2016;40(4):304–14.27061298 10.1002/gepi.21965
37. Wang S Zhu H Pan L Zhang M Wan X Xu H Systemic inflammatory regulators and risk of acute-on-chronic liver failure: A bidirectional mendelian-randomization study Front Cell Dev Biol 2023 11 1125233 10.3389/fcell.2023.1125233 36743413
Wang S, Zhu H, Pan L, Zhang M, Wan X, Xu H, et al. Systemic inflammatory regulators and risk of acute-on-chronic liver failure: A bidirectional mendelian-randomization study. Front Cell Dev Biol. 2023;11:1125233.36743413 10.3389/fcell.2023.1125233
38. Sanderson E. Multivariable Mendelian Randomization and Mediation. Cold Spring Harb Perspect Med. 2021;11(2):a038984.
39. Shu MJ Li JR Zhu YC Shen H Migraine and Ischemic Stroke: A Mendelian Randomization Study Neurol Ther 2022 11 1 237 246 10.1007/s40120-021-00310-y 34904213
Shu MJ, Li JR, Zhu YC, Shen H. Migraine and Ischemic Stroke: A Mendelian Randomization Study. Neurol Ther. 2022;11(1):237–46.34904213 10.1007/s40120-021-00310-y
40. He J, Luo X, Xin H, Lai Q, Zhou Y, Bai Y. The Effects of Fatty Acids on Inflammatory Bowel Disease: A Two-Sample Mendelian Randomization Study. Nutrients. 2022;14(14):2883.
41. Verbanck M Chen CY Neale B Do R Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases Nat Genet 2018 50 5 693 698 10.1038/s41588-018-0099-7 29686387
Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50(5):693–8.29686387 10.1038/s41588-018-0099-7
42. Greco MF Minelli C Sheehan NA Thompson JR Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome Stat Med 2015 34 21 2926 2940 10.1002/sim.6522 25950993
Greco MF, Minelli C, Sheehan NA, Thompson JR. Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome. Stat Med. 2015;34(21):2926–40.25950993 10.1002/sim.6522
43. Zhang J Mendelian Randomization Study Implies Causal Linkage Between Telomere Length and Juvenile Idiopathic Arthritis in a European Population J Inflamm Res 2022 15 977 986 10.2147/JIR.S354619 35210806
Zhang J. Mendelian Randomization Study Implies Causal Linkage Between Telomere Length and Juvenile Idiopathic Arthritis in a European Population. J Inflamm Res. 2022;15:977–86.35210806 10.2147/JIR.S354619
44. Zhao Q Chen Y Wang J Small DS Powerful three-sample genome-wide design and robust statistical inference in summary-data Mendelian randomization Int J Epidemiol 2019 48 5 1478 1492 10.1093/ije/dyz142 31298269
Zhao Q, Chen Y, Wang J, Small DS. Powerful three-sample genome-wide design and robust statistical inference in summary-data Mendelian randomization. Int J Epidemiol. 2019;48(5):1478–92.31298269 10.1093/ije/dyz142
45. Niu W Gu M Adding Mendelian randomization to a meta-analysis-a burgeoning opportunity Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2016 37 2 1527 1529 10.1007/s13277-015-4680-8 26695146
Niu W, Gu M. Adding Mendelian randomization to a meta-analysis-a burgeoning opportunity. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2016;37(2):1527–9.26695146 10.1007/s13277-015-4680-8
46. Freuer D Meisinger C Association between inflammatory bowel disease and Parkinson's disease: A Mendelian randomization study NPJ Parkinson's disease 2022 8 1 55 10.1038/s41531-022-00318-7 35534507
Freuer D, Meisinger C. Association between inflammatory bowel disease and Parkinson’s disease: A Mendelian randomization study. NPJ Parkinson’s disease. 2022;8(1):55.35534507 10.1038/s41531-022-00318-7
47. Jackson D White IR Riley RD Quantifying the impact of between-study heterogeneity in multivariate meta-analyses Stat Med 2012 31 29 3805 3820 10.1002/sim.5453 22763950
Jackson D, White IR, Riley RD. Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Stat Med. 2012;31(29):3805–20.22763950 10.1002/sim.5453
48. Labenz C Huber Y Michel M Nagel M Galle PR Kostev K Nonalcoholic Fatty Liver Disease Increases the Risk of Anxiety and Depression Hepatology Communications 2020 4 9 1293 1301 10.1002/hep4.1541 32923833
Labenz C, Huber Y, Michel M, Nagel M, Galle PR, Kostev K, et al. Nonalcoholic Fatty Liver Disease Increases the Risk of Anxiety and Depression. Hepatology Communications. 2020;4(9):1293–301.32923833 10.1002/hep4.1541
49. Youssef NA Abdelmalek MF Binks M Guy CD Omenetti A Smith AD Associations of depression, anxiety and antidepressants with histological severity of nonalcoholic fatty liver disease Liver Int 2013 33 7 1062 1070 10.1111/liv.12165 23560860
Youssef NA, Abdelmalek MF, Binks M, Guy CD, Omenetti A, Smith AD, et al. Associations of depression, anxiety and antidepressants with histological severity of nonalcoholic fatty liver disease. Liver Int. 2013;33(7):1062–70.23560860 10.1111/liv.12165
50. Cohen JC Horton JD Hobbs HH Human Fatty Liver Disease: Old Questions and New Insights Science 2011 332 6037 1519 1523 10.1126/science.1204265 21700865
Cohen JC, Horton JD, Hobbs HH. Human Fatty Liver Disease: Old Questions and New Insights. Science. 2011;332(6037):1519–23.21700865 10.1126/science.1204265
51. Elwing JE Lustman PJ Wang HL Clouse RE Depression, Anxiety, and Nonalcoholic Steatohepatitis Psychosom Med 2006 68 4 563 569 10.1097/01.psy.0000221276.17823.df 16868265
Elwing JE, Lustman PJ, Wang HL, Clouse RE. Depression, Anxiety, and Nonalcoholic Steatohepatitis. Psychosom Med. 2006;68(4):563–9.16868265 10.1097/01.psy.0000221276.17823.df
52. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1545–602.
53. Milaneschi Y Simmons WK van Rossum EFC Penninx BW Depression and obesity: evidence of shared biological mechanisms Mol Psychiatry 2019 24 1 18 33 10.1038/s41380-018-0017-5 29453413
Milaneschi Y, Simmons WK, van Rossum EFC, Penninx BW. Depression and obesity: evidence of shared biological mechanisms. Mol Psychiatry. 2019;24(1):18–33.29453413 10.1038/s41380-018-0017-5
54. Kim D Yoo ER Li AA Tighe SP Cholankeril G Harrison SA Depression is associated with non-alcoholic fatty liver disease among adults in the United States Aliment Pharmacol Ther 2019 50 5 590 598 10.1111/apt.15395 31328300
Kim D, Yoo ER, Li AA, Tighe SP, Cholankeril G, Harrison SA, et al. Depression is associated with non-alcoholic fatty liver disease among adults in the United States. Aliment Pharmacol Ther. 2019;50(5):590–8.31328300 10.1111/apt.15395
55. Ng CH Xiao J Chew NWS Chin YH Chan KE Quek J Depression in non-alcoholic fatty liver disease is associated with an increased risk of complications and mortality Front Med (Lausanne) 2022 9 985803 10.3389/fmed.2022.985803 36275825
Ng CH, Xiao J, Chew NWS, Chin YH, Chan KE, Quek J, et al. Depression in non-alcoholic fatty liver disease is associated with an increased risk of complications and mortality. Front Med (Lausanne). 2022;9.36275825 10.3389/fmed.2022.985803
56. Tomeno W Kawashima K Yoneda M Saito S Ogawa Y Honda Y Non-alcoholic fatty liver disease comorbid with major depressive disorder: The pathological features and poor therapeutic efficacy J Gastroenterol Hepatol 2015 30 6 1009 1014 10.1111/jgh.12897 25619308
Tomeno W, Kawashima K, Yoneda M, Saito S, Ogawa Y, Honda Y, et al. Non-alcoholic fatty liver disease comorbid with major depressive disorder: The pathological features and poor therapeutic efficacy. J Gastroenterol Hepatol. 2015;30(6):1009–14.25619308 10.1111/jgh.12897
57. Tokushige K Ikejima K Ono M Eguchi Y Kamada Y Itoh Y Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020 J Gastroenterol 2021 56 11 951 963 10.1007/s00535-021-01796-x 34533632
Tokushige K, Ikejima K, Ono M, Eguchi Y, Kamada Y, Itoh Y, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. J Gastroenterol. 2021;56(11):951–63.34533632 10.1007/s00535-021-01796-x
58. Kraus C Kadriu B Lanzenberger R Zarate CA Jr Kasper S Prognosis and improved outcomes in major depression: a review Transl Psychiatry 2019 9 1 127 10.1038/s41398-019-0460-3 30944309
Kraus C, Kadriu B, Lanzenberger R, Zarate CA Jr, Kasper S. Prognosis and improved outcomes in major depression: a review. Transl Psychiatry. 2019;9(1):127.30944309 10.1038/s41398-019-0460-3
59. Knol MJ Twisk JW Beekman AT Heine RJ Snoek FJ Pouwer F Depression as a risk factor for the onset of type 2 diabetes mellitus A meta-analysis Diabetologia 2006 49 5 837 845 16520921
Knol MJ, Twisk JW, Beekman AT, Heine RJ, Snoek FJ, Pouwer F. Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis Diabetologia. 2006;49(5):837–45.16520921
60. Björntorp P Do stress reactions cause abdominal obesity and comorbidities? Obesity reviews : an official journal of the International Association for the Study of Obesity 2001 2 2 73 86 10.1046/j.1467-789x.2001.00027.x 12119665
Björntorp P. Do stress reactions cause abdominal obesity and comorbidities? Obesity reviews : an official journal of the International Association for the Study of Obesity. 2001;2(2):73–86.12119665 10.1046/j.1467-789x.2001.00027.x
61. Khan RS Bril F Cusi K Newsome PN Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease Hepatology (Baltimore, MD) 2019 70 2 711 724 10.1002/hep.30429 30556145
Khan RS, Bril F, Cusi K, Newsome PN. Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease. Hepatology (Baltimore, MD). 2019;70(2):711–24.30556145 10.1002/hep.30429
62. Shang Y Nasr P Ekstedt M Widman L Stål P Hultcrantz R Non-alcoholic fatty liver disease does not increase dementia risk although histology data might improve risk prediction JHEP reports : innovation in hepatology 2021 3 2 100218 10.1016/j.jhepr.2020.100218 33554097
Shang Y, Nasr P, Ekstedt M, Widman L, Stål P, Hultcrantz R, et al. Non-alcoholic fatty liver disease does not increase dementia risk although histology data might improve risk prediction. JHEP reports : innovation in hepatology. 2021;3(2).33554097 10.1016/j.jhepr.2020.100218
63. Huang H Liu Z Xie J Xu C NAFLD does not increase the risk of incident dementia: A prospective study and meta-analysis J Psychiatr Res 2023 161 435 440 10.1016/j.jpsychires.2023.03.041 37043979
Huang H, Liu Z, Xie J, Xu C. NAFLD does not increase the risk of incident dementia: A prospective study and meta-analysis. J Psychiatr Res. 2023;161:435–40.37043979 10.1016/j.jpsychires.2023.03.041
64. Weinstein G Davis-Plourde K Himali JJ Zelber-Sagi S Beiser AS Seshadri S Non-alcoholic fatty liver disease, liver fibrosis score and cognitive function in middle-aged adults: The Framingham Study Liver international : official journal of the International Association for the Study of the Liver 2019 39 9 1713 1721 10.1111/liv.14161 31155826
Weinstein G, Davis-Plourde K, Himali JJ, Zelber-Sagi S, Beiser AS, Seshadri S. Non-alcoholic fatty liver disease, liver fibrosis score and cognitive function in middle-aged adults: The Framingham Study. Liver international : official journal of the International Association for the Study of the Liver. 2019;39(9):1713–21.31155826 10.1111/liv.14161
65. Solfrizzi V Scafato E Custodero C Loparco F Ciavarella A Panza F Liver fibrosis score, physical frailty, and the risk of dementia in older adults: The Italian Longitudinal Study on Aging Alzheimer's & dementia (New York, N Y) 2020 6 1 e12065 10.1002/trc2.12065
Solfrizzi V, Scafato E, Custodero C, Loparco F, Ciavarella A, Panza F, et al. Liver fibrosis score, physical frailty, and the risk of dementia in older adults: The Italian Longitudinal Study on Aging. Alzheimer’s & dementia (New York, N Y). 2020;6(1): e12065.10.1002/trc2.12065
66. Long MT Wang N Larson MG Mitchell GF Palmisano J Vasan RS Nonalcoholic fatty liver disease and vascular function: cross-sectional analysis in the Framingham heart study Arterioscler Thromb Vasc Biol 2015 35 5 1284 1291 10.1161/ATVBAHA.114.305200 25745056
Long MT, Wang N, Larson MG, Mitchell GF, Palmisano J, Vasan RS, et al. Nonalcoholic fatty liver disease and vascular function: cross-sectional analysis in the Framingham heart study. Arterioscler Thromb Vasc Biol. 2015;35(5):1284–91.25745056 10.1161/ATVBAHA.114.305200
67. Kim SU Song D Heo JH Yoo J Kim BK Park JY Liver fibrosis assessed with transient elastography is an independent risk factor for ischemic stroke Atherosclerosis 2017 260 156 162 10.1016/j.atherosclerosis.2017.02.005 28222857
Kim SU, Song D, Heo JH, Yoo J, Kim BK, Park JY, et al. Liver fibrosis assessed with transient elastography is an independent risk factor for ischemic stroke. Atherosclerosis. 2017;260:156–62.28222857 10.1016/j.atherosclerosis.2017.02.005
68. Godin O Leboyer M Belzeaux R Bellivier F Loftus J Courtet P Non-alcoholic fatty liver disease in a sample of individuals with bipolar disorders: results from the FACE-BD cohort Acta Psychiatr Scand 2020 143 1 82 91 10.1111/acps.13239 33011976
Godin O, Leboyer M, Belzeaux R, Bellivier F, Loftus J, Courtet P, et al. Non-alcoholic fatty liver disease in a sample of individuals with bipolar disorders: results from the FACE-BD cohort. Acta Psychiatr Scand. 2020;143(1):82–91.33011976 10.1111/acps.13239
69. May M, Barlow D, Ibrahim R, Houseknecht KL. Mechanisms Underlying Antipsychotic-Induced NAFLD and Iron Dysregulation: A Multi-Omic Approach. Biomedicines. 2022;10(6):1225.
70. Renn BN Feliciano L Segal DL The bidirectional relationship of depression and diabetes: a systematic review Clin Psychol Rev 2011 31 8 1239 1246 10.1016/j.cpr.2011.08.001 21963669
Renn BN, Feliciano L, Segal DL. The bidirectional relationship of depression and diabetes: a systematic review. Clin Psychol Rev. 2011;31(8):1239–46.21963669 10.1016/j.cpr.2011.08.001
71. Cao H, Baranova A, Zhao Q, Zhang F. Bidirectional associations between mental disorders, antidepressants and cardiovascular disease. BMJ Ment Health. 2024;27(1):e300975.
72. Yan J Hou C Liang Y The prevalence and risk factors of young male schizophrenics with non-alcoholic fatty liver disease Neuropsychiatr Dis Treat 2017 13 1493 1498 10.2147/NDT.S137183 28652750
Yan J, Hou C, Liang Y. The prevalence and risk factors of young male schizophrenics with non-alcoholic fatty liver disease. Neuropsychiatr Dis Treat. 2017;13:1493–8.28652750 10.2147/NDT.S137183
73. Pillinger T Beck K Gobjila C Donocik JG Jauhar S Howes OD Impaired Glucose Homeostasis in First-Episode Schizophrenia: A Systematic Review and Meta-analysis JAMA Psychiat 2017 74 3 261 269 10.1001/jamapsychiatry.2016.3803
Pillinger T, Beck K, Gobjila C, Donocik JG, Jauhar S, Howes OD. Impaired Glucose Homeostasis in First-Episode Schizophrenia: A Systematic Review and Meta-analysis. JAMA Psychiat. 2017;74(3):261–9.10.1001/jamapsychiatry.2016.3803
74. Wrigglesworth J Ward P Harding IH Nilaweera D Wu Z Woods RL Factors associated with brain ageing - a systematic review BMC Neurol 2021 21 1 312 10.1186/s12883-021-02331-4 34384369
Wrigglesworth J, Ward P, Harding IH, Nilaweera D, Wu Z, Woods RL, et al. Factors associated with brain ageing - a systematic review. BMC Neurol. 2021;21(1):312.34384369 10.1186/s12883-021-02331-4
75. Baranova A Zhao Q Cao H Chandhoke V Zhang F Causal influences of neuropsychiatric disorders on Alzheimer's disease Transl Psychiatry 2024 14 1 114 10.1038/s41398-024-02822-1 38395927
Baranova A, Zhao Q, Cao H, Chandhoke V, Zhang F. Causal influences of neuropsychiatric disorders on Alzheimer’s disease. Transl Psychiatry. 2024;14(1):114.38395927 10.1038/s41398-024-02822-1
76. Roth T Insomnia: definition, prevalence, etiology, and consequences Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2007 3 5 Suppl S7 10 17824495
Roth T. Insomnia: definition, prevalence, etiology, and consequences. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2007;3(5 Suppl):S7-10.17824495
77. Donga E van Dijk M van Dijk JG Biermasz NR Lammers GJ van Kralingen KW A single night of partial sleep deprivation induces insulin resistance in multiple metabolic pathways in healthy subjects J Clin Endocrinol Metab 2010 95 6 2963 2968 10.1210/jc.2009-2430 20371664
Donga E, van Dijk M, van Dijk JG, Biermasz NR, Lammers GJ, van Kralingen KW, et al. A single night of partial sleep deprivation induces insulin resistance in multiple metabolic pathways in healthy subjects. J Clin Endocrinol Metab. 2010;95(6):2963–8.20371664 10.1210/jc.2009-2430
78. Gulec M Ozkol H Selvi Y Tuluce Y Aydin A Besiroglu L Oxidative stress in patients with primary insomnia Prog Neuropsychopharmacol Biol Psychiatry 2012 37 2 247 251 10.1016/j.pnpbp.2012.02.011 22401887
Gulec M, Ozkol H, Selvi Y, Tuluce Y, Aydin A, Besiroglu L, et al. Oxidative stress in patients with primary insomnia. Prog Neuropsychopharmacol Biol Psychiatry. 2012;37(2):247–51.22401887 10.1016/j.pnpbp.2012.02.011
79. Irie M Sohda T Iwata K Kunimoto H Fukunaga A Kuno S Levels of the oxidative stress marker γ-glutamyltranspeptidase at different stages of nonalcoholic fatty liver disease J Int Med Res 2012 40 3 924 933 10.1177/147323001204000311 22906265
Irie M, Sohda T, Iwata K, Kunimoto H, Fukunaga A, Kuno S, et al. Levels of the oxidative stress marker γ-glutamyltranspeptidase at different stages of nonalcoholic fatty liver disease. J Int Med Res. 2012;40(3):924–33.22906265 10.1177/147323001204000311
80. Taketani H Sumida Y Tanaka S Imajo K Yoneda M Hyogo H The association of insomnia with gastroesophageal reflux symptoms in biopsy-proven nonalcoholic fatty liver disease J Gastroenterol 2014 49 7 1163 1174 10.1007/s00535-013-0871-5 23975270
Taketani H, Sumida Y, Tanaka S, Imajo K, Yoneda M, Hyogo H, et al. The association of insomnia with gastroesophageal reflux symptoms in biopsy-proven nonalcoholic fatty liver disease. J Gastroenterol. 2014;49(7):1163–74.23975270 10.1007/s00535-013-0871-5
81. Martami F Ghorbani Z Abolhasani M Togha M Meysamie A Sharifi A Comorbidity of gastrointestinal disorders, migraine, and tension-type headache: a cross-sectional study in Iran Neurol Sci 2018 39 1 63 70 10.1007/s10072-017-3141-0 29022143
Martami F, Ghorbani Z, Abolhasani M, Togha M, Meysamie A, Sharifi A, et al. Comorbidity of gastrointestinal disorders, migraine, and tension-type headache: a cross-sectional study in Iran. Neurol Sci. 2018;39(1):63–70.29022143 10.1007/s10072-017-3141-0
82. Celikbilek A Celikbilek M Okur A Dogan S Borekci E Kozan M Non-alcoholic fatty liver disease in patients with migraine Neurol Sci 2014 35 10 1573 1578 10.1007/s10072-014-1798-1 24756192
Celikbilek A, Celikbilek M, Okur A, Dogan S, Borekci E, Kozan M, et al. Non-alcoholic fatty liver disease in patients with migraine. Neurol Sci. 2014;35(10):1573–8.24756192 10.1007/s10072-014-1798-1
83. Andreu-Bernabeu Á, González-Peñas J, Arango C, Díaz-Caneja CM. Socioeconomic status and severe mental disorders: a bidirectional multivariable Mendelian randomisation study. BMJ Ment Health. 2023;26(1):e300821.
84. Howe LJ Tudball M Davey Smith G Davies NM Interpreting Mendelian-randomization estimates of the effects of categorical exposures such as disease status and educational attainment Int J Epidemiol 2022 51 3 948 957 10.1093/ije/dyab208 34570226
Howe LJ, Tudball M, Davey Smith G, Davies NM. Interpreting Mendelian-randomization estimates of the effects of categorical exposures such as disease status and educational attainment. Int J Epidemiol. 2022;51(3):948–57.34570226 10.1093/ije/dyab208
85. Vilar-Gomez E Nephew LD Vuppalanchi R Gawrieh S Mladenovic A Pike F High-quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population Hepatology (Baltimore, MD) 2022 75 6 1491 1506 10.1002/hep.32207 34668597
Vilar-Gomez E, Nephew LD, Vuppalanchi R, Gawrieh S, Mladenovic A, Pike F, et al. High-quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population. Hepatology (Baltimore, MD). 2022;75(6):1491–506.34668597 10.1002/hep.32207
86. Burgess S Butterworth A Thompson SG Mendelian randomization analysis with multiple genetic variants using summarized data Genet Epidemiol 2013 37 7 658 665 10.1002/gepi.21758 24114802
Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol. 2013;37(7):658–65.24114802 10.1002/gepi.21758
87. Ference BA Majeed F Penumetcha R Flack JM Brook RD Effect of Naturally Random Allocation to Lower Low-Density Lipoprotein Cholesterol on the Risk of Coronary Heart Disease Mediated by Polymorphisms in NPC1L1, HMGCR, or Both J Am Coll Cardiol 2015 65 15 1552 1561 10.1016/j.jacc.2015.02.020 25770315
Ference BA, Majeed F, Penumetcha R, Flack JM, Brook RD. Effect of Naturally Random Allocation to Lower Low-Density Lipoprotein Cholesterol on the Risk of Coronary Heart Disease Mediated by Polymorphisms in NPC1L1, HMGCR, or Both. J Am Coll Cardiol. 2015;65(15):1552–61.25770315 10.1016/j.jacc.2015.02.020
